FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Australia (AU)
Overview
Projects
(26)
Publications
(2,645)
External partners
(329)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020)
Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al.
Journal article
CROSSED PRODUCTS OF C*-ALGEBRAS FOR SINGULAR ACTIONS WITH SPECTRUM CONDITIONS (2020)
Grundling H, Neeb KH
Journal article
Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020)
Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al.
Conference contribution
EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020)
Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al.
Conference contribution
Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al.
Conference contribution
Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (2020)
Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, et al.
Conference contribution
Latency and Reliability of mmWave Multi-Hop V2V Communications Under Relay Selections (2020)
Li Z, Xiang L, Ge X, Mao G, Chao HC
Journal article
γ-ray emission in radio galaxies under the VLBI scope: II. The relationship between γ-ray emission and parsec-scale jets in radio galaxies (2020)
Angioni R, Ros E, Kadler M, Ojha R, Mueller C, Edwards PG, Burd PR, et al.
Journal article
Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). (2020)
Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, et al.
Conference contribution
Accelerated Partial Breast Irradiation: Identification of High Risk Tumors in Early Hormone Receptor-positive Breast Cancer by Macrophage Shift Classification (2020)
Schnellhardt S, Erber R, Büttner-Herold M, Rosahl MC, Ott O, Strnad V, Beckmann M, et al.
Conference contribution
‹
1
...
98
99
100
101
102
...
265
›